ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...

The physician at the tech giant: “Observations in the emergency room made my mind up”

When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Pharma Outsourcing – Find the Right Partner (2025)

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Hundratals AI-projekt leder Astra Zeneca mot ambitiösa målet

Astra Zeneca arbetar för att ligga i framkant inom AI, en bärande faktor för att bolaget ska nå sitt mål om att lansera 20 nya läkemedel till år 2030. ”Om man inte använder AI för sin läkemedelsutveckling kommer man att tappa hårt i konkurrenskraft...

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

GU Ventures AB

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease

According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...

Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study

In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one...

Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

New rules for diagnostic products, but who will certify them? “An extreme shortage area”

In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and...

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that it will change,” says...

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

Rapport: Två av tre biotechbolag med AI-satsning ser bättre resultat

Företag inom life science ligger i framkant när det gäller att använda AI – både i bredd och mognad. Två av tre biotechbolag som satsar strategiskt på tekniken ...

The Future of Swedish & Danish Life Science (2026)

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Nytt världsrekord i labbet – kartlade arvsmassa på fyra timmar

Roche har slagit världsrekord av ett annorlunda slag – genom att sekvensera ett komplett mänskligt genom på mindre än fyra timmar.

JMP Statistical Discovery

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

How to Assure Quality within R&D Medical Devices

Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.